Physician profile
Joy Ellen Bowling
NPI 1356064273
$1,841.70
in general payments reported to CMS, 2019-2025
35 companies · $567 in 2025
The $567 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.22 · 2023: $709 · 2024: $548 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $174.25 | 2023 | Mounjaro, Trulicity |
| Dexcom, INC. | $160.46 | 2024-2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $150.13 | 2024-2025 | Triptodur |
| Ascendis Pharma Endocrinology INC | $134.38 | 2024-2025 | Skytrofa |
| Ucb, INC. | $113.87 | 2024-2025 | Fintepla, Briviact |
| Tandem Diabetes Care, INC. | $90.16 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $85.32 | 2023-2024 | |
| Pfizer INC. | $72.50 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.01 | 2022-2024 | Eohilia, Trintellix |
| Amphastar Pharmaceuticals, INC. | $61.96 | 2024-2025 | |
| Medtronic, INC. | $61.62 | 2023 | Guardian Connect |
| Abbott Laboratories | $56.13 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $46.83 | 2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $46.01 | 2023-2024 | |
| Smith+Nephew, INC. | $42.70 | 2023 | Collagenase Santyl, Pico |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $40.94 | 2024-2025 | |
| Soleno Therapeutics, INC. | $39.99 | 2025 | Vykat Xr |
| Astrazeneca Pharmaceuticals LP | $39.76 | 2023 | Farxiga, Breztri |
| Novo Nordisk INC | $38.82 | 2023 | Ozempic |
| Ipsen Biopharmaceuticals, INC | $35.36 | 2024-2025 | Bylvay |
| Sanofi-Aventis U.S. LLC | $25.75 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $25.51 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $24.74 | 2023 | Rotateq, Vaxelis, Vaqta |
| Radius Health, INC. | $23.26 | 2023 | Tymlos |
| Tolmar, INC. | $22.11 | 2025 | Fensolvi |
| Sequel Med Tech, LLC | $21.14 | 2025 | Twiist |
| Qol Medical, LLC | $20.31 | 2025 | Sucraid |
| Lundbeck LLC | $18.99 | 2023 | Rexulti |
| Amgen INC. | $16.02 | 2023 | Repatha |
| Exact Sciences Corporation | $15.64 | 2023 | Cologuard Collection Kit |
| Averitas Pharma INC. | $15.32 | 2023 | Qutenza |
| Indivior INC. | $14.50 | 2023 | Sublocade |
| Glaxosmithkline, LLC. | $14.37 | 2023 | Trelegy Ellipta |
| Integra Lifesciences Corporation | $13.12 | 2023 | Tcc-Ez |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.